{
  "abstract": "Introduction: We reviewed the clinical studies on fibroblast growth factor receptor (FGFR) inhibitors for the treatment of urothelial carcinoma to conduct the meta-analysis of clinical efficacy and safety, aiming to provide more precise treatment options for patients with FGFR alterations.\n\nMethod: We performed the literature search and screening, then calculated and analyzed using the STATA 14.0 software and Review Manager 5.3 software.\n\nResults: A total of 1528 patients from seventeen studies focusing on seven different FGFR inhibitors were collected. The efficacy analysis indicated the pooled objective response rate (ORR) was 32% (95% CI 26% to 39%) and the pooled disease control rate (DCR) was 64% (95% CI 53% to 75%) for patients with FGFR alterations treated with FGFR inhibitors. The pooled ORR and DCR of second-generation FGFR inhibitors were both significantly higher than those of first-generation FGFR inhibitors (ORR: 0.35, 95% CI 0.29 to 0.41 versus 0.07, 95% CI 0.02 to 0.16, p < 0.001; DCR: 0.68, 95% CI 0.61 to 0.75 versus 0.27, 95% CI 0.16 to 0.40, p < 0.001). The safety analysis indicated any-grade TRAEs were comparable between first- and second-generation FGFR inhibitors, but grade ≥3 TRAEs were significantly less frequent with second-generation FGFR inhibitors versus first-generation FGFR inhibitors (0.49, 95% CI 0.40 to 0.57 versus 0.67, 95% CI 0.57 to 0.76; p = 0.006). The common target toxicities associated with FGFR inhibitors, such as hyperphosphatemia, stomatitis and PPES, were more frequently occurred in second-generation FGFR inhibitors compared to first-generation FGFR inhibitors.\n\nConclusion: The second-generation FGFR inhibitors have advantages in both efficacy and safety, but special adverse reactions still require additional attention.",
  "abstract_shown": true,
  "affiliations": [
    "Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute , ,"
  ],
  "article_type": "systematic review",
  "arxiv": null,
  "author_total": 4,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Zhe Wang"
    },
    {
      "affs": [
        0
      ],
      "name": "Bo Shao"
    },
    {
      "affs": [
        0
      ],
      "name": "Danxue Huang"
    },
    {
      "affs": [
        0
      ],
      "name": "Liyuan Ke"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/2qxrsq8vaymrq.bib",
  "cited_by": 0,
  "doi": "10.3389/fphar.2026.1850131",
  "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13662917/?tool=EBI",
  "id": "2qxrsq8vaymrq",
  "issns": [
    "1663-9812"
  ],
  "landing_url": "https://europepmc.org/article/PMC/PMC13662917",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2746|Bladder and Urothelial Cancer Treatments"
    ]
  ],
  "openalex": "W7214975362",
  "pdf_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13662917/pdf/?tool=EBI",
  "pmcid": "PMC13662917",
  "pmid": null,
  "published": "2026-09-30",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/2qxrsq8vaymrq.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:20Z",
      "native_id": "PMC:PMC13662917",
      "source": "europepmc",
      "url": "https://europepmc.org/article/PMC/PMC13662917"
    },
    {
      "first_seen": "2026-10-30T12:20:06Z",
      "native_id": "10.3389/fphar.2026.1850131",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fphar.2026.1850131/full"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2746|Bladder and Urothelial Cancer Treatments",
      "subfield": "surgery"
    }
  ],
  "title": "Efficacy and safety of first- versus second-generation fibroblast growth factor receptor (FGFR) inhibitors in advanced or metastatic urothelial carcinoma with FGFR alterations: a systematic review and meta-analysis",
  "title_text": "Efficacy and safety of first- versus second-generation fibroblast growth factor receptor (FGFR) inhibitors in advanced or metastatic urothelial carcinoma with FGFR alterations: a systematic review and meta-analysis",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:20:06Z",
  "url": "https://research.draconitic.com/paper/2qxrsq8vaymrq",
  "venue": "Frontiers in pharmacology",
  "versions": []
}